Clinical significance of evaluating primary lesions in patients with gastric cancer who receive chemotherapy
- 1.4k Downloads
- 2 Citations
Abstract
Background
In Western countries, the response of gastric cancer to chemotherapy is evaluated by assessing measurable metastatic lesions (MMLs) according to the response evaluation criteria in solid tumors (RECIST). In Japan, the response of primary lesions is assessed according to local Japanese criteria. We compared the response to chemotherapy as evaluated by these two sets of criteria.
Methods
Patients with unresectable, advanced gastric cancer who had primary lesions and had received first-line chemotherapy were studied. Responses of MMLs were evaluated with RECIST. Responses of primary lesions were evaluated with the Japanese criteria. Median survival times (MSTs) were compared according to treatment response by each set of criteria.
Results
Data from 341 patients were analyzed. Of the 242 patients with MMLs, 108 were MML responders and 134 were MML nonresponders. MST was significantly longer in MML responders (293 days; 95% confidence interval [CI], 244–342) than in MML nonresponders (159 days; 95% CI, 127–191; P < 0.0001). According to the Japanese criteria, there were 128 primary-lesion responders and 213 primary-lesion nonresponders. MST was significantly longer in responders (304 days; 95% CI, 266–342) than in nonresponders (168 days; 95% CI, 143–193, P < 0.0001). Of the 99 patients without MMLs, 26 were primary-lesion responders and 73, primary-lesion nonresponders; MST was significantly longer in the former (300 days; 95% CI, 266–334) than in the latter group (173 days; 95% CI, 111–235; P = 0.019).
Conclusion
The responses of primary lesions according to the Japanese criteria and the responses of MMLs according to the RECIST were both significantly related to the MST. Use of the RECIST alone might bias the evaluation of treatment response because response cannot be evaluated in patients without an MML.
Key words
Gastric cancer Chemotherapy Primary lesion RECISTReferences
- 1.Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205–216.CrossRefPubMedGoogle Scholar
- 2.Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma — 2nd English edition —. Gastric Cancer 1998;1:10–24.CrossRefPubMedGoogle Scholar
- 3.Koizumi W, Kurihara M, Tanabe S, Kondo I, Yamazaki I, Nonaka M, et al. Advantages of Japanese response criteria for estimating the survival of patients with primary gastric cancer. Gastric Cancer 1999;2:14–19.CrossRefPubMedGoogle Scholar
- 4.Kiyohashi A, Kurihara M, Yoshida S, Ohkubo T, Suga S. Antitumor effect and survival benefit of chemotherapy for unresectable advanced gastric cancer. Jpn J Clin Oncol 1993;23:41–45.PubMedGoogle Scholar
- 5.Yoshida S, Miyata Y, Ohtsu A, Boku N, Shirao K, Shimada Y. Significance of and problems in adopting response evaluation criteria in solid tumor RECIST for assessing anticancer effects of advanced gastric cancer. Gastric Cancer 2000;3:128–133.CrossRefPubMedGoogle Scholar
- 6.Ohtsu A, Boku N, Yoshida S, Miyata Y, Shirao K, Shimada Y, et al. Response of the primary lesion in gastric cancer to chemotherapeutic trials. Int J Clin Oncol 1998;3:3–6.CrossRefGoogle Scholar
- 7.Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol 1983;11:710–719.Google Scholar
- 8.Maruyama K, Okabayashi K, Kinoshita T. Progress in gastric cancer surgery in Japan and its limits of radicality. World J Surg 1987;11:418–425.CrossRefPubMedGoogle Scholar
- 9.Konishi T, Hiraishi M, Mafune K, Miyama T, Hirata T, Mori K, et al. Therapeutic efficacy and toxicity of sequential methotrexate and 5-fluorouracil in gastric cancer. Anticancer Res 1994;14:1277–1279.PubMedGoogle Scholar
- 10.Kikuchi S, Kida M, Kobayashi K, Yano T, Sakuramoto S, Watanabe M, et al. New diagnostic imaging of gastrointestinal tumors: a preliminary study of three-dimensional tumor structure and volumetry. Anticancer Res 2005;25:2935–2941.PubMedGoogle Scholar
- 11.Kim JH, Park SH, Hong HS, Auh YH. CT gastrography. Abdom Imaging 2005;30:509–517.CrossRefPubMedGoogle Scholar
- 12.Kim AY, Kim HJ, Ha HK. Gastric cancer by multidetector row CT: preoperative staging. Abdom Imaging 2005;30:465–472.CrossRefPubMedGoogle Scholar